Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer

Publication date: November 2017
Source:International Immunopharmacology, Volume 52
Author(s): Qiaohong Wang, Weihua Lou, Wen Di, Xia Wu
Expression of programmed cell death-ligand 1 (PD-L1) is known to be a mechanism whereby cancer can escape immune surveillance, but the relationship between tumor PD-L1 expression and tumor-infiltrating lymphocytes (TILs), and their association with clinical outcomes in patients with high grade serous ovarian cancer (HGSOC) remain ambiguous. We detected the expression of PD-L1 and CD3⁺, CD4⁺, CD8⁺ TILs in 107 patients with HGSOC by immunohistochemical analysis. Using a 5% threshold, 24.30% and 15.89% cases were found with positive expression of PD-L1 in the membrane of tumor cells and TILs respectively. Carcinoma PD-L1 expression mainly localized to the tumor invasive front and was associated with advanced FIGO stage (p=0.023) and abundant stromal CD8⁺ TILs infiltration (p=0.020). Tumors containing PD-L1⁺ TILs were more likely to have PD-L1 expression by the carcinoma cells (p<0.001). Univariate and multivariate analyses demonstrated that a higher number of intraepithelial CD3⁺ or CD8⁺ TILs was an independent prognostic factor for longer overall survival (OS), whereas tumor PD-L1 expression was a predictive factor for poorer OS only in univariate analysis. PD-L1 expression in TILs was not a prognostic factor in univariate analysis. The Kaplan-Meier curves of the four sub-groups and log-rank test showed that patients with negative tumor PD-L1 expression/higher numbers of intraepithelial CD8⁺ TILs had the longest median OS, while those with positive tumor PD-L1 expression/lower numbers of intraepithelial CD8⁺ TILs had the shortest median OS (p<0.001). Our results indicate that tumor PD-L1 expression in combination with intraepithelial CD8⁺ TILs infiltration has prognostic impact in patients with HGSOC. These biomarkers may be useful for the stratification of patients. Further evaluation of PD-1/PD-L1 as therapeutic targets for HGSOC is warranted.



http://ift.tt/2vwgAju